This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
How Much Upside is Left in Viridian Therapeutics, Inc. (VRDN)? Wall Street Analysts Think 97.81%
by Zacks Equity Research
The mean of analysts' price targets for Viridian Therapeutics, Inc. (VRDN) points to a 97.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of 24.56% and 31.69%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Janux Therapeutics, Inc. (JANX) Moves 5.6% Higher: Will This Strength Last?
by Zacks Equity Research
Janux Therapeutics, Inc. (JANX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of 10.66% and 74.38%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Viridian Therapeutics, Inc. (VRDN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Viridian Therapeutics, Inc. (VRDN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Viridian Therapeutics, Inc. (VRDN) Stock Jumps 5.2%: Will It Continue to Soar?
by Zacks Equity Research
Viridian Therapeutics, Inc. (VRDN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of -0.79% and 78.18%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Sarepta Therapeutics (SRPT) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 85.71% and 1.21%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Viridian Therapeutics, Inc. (VRDN) is Poised for a Turnaround After Losing -20.23% in 4 Weeks
by Zacks Equity Research
Viridian Therapeutics, Inc. (VRDN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of -61% and 67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of -56.94% and 85.25%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Cara Therapeutics (CARA) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cara (CARA) delivered earnings and revenue surprises of -69.70% and 76.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Syros Pharmaceuticals, Inc. (SYRS) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of -0.79% and 123.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Predict an 89% Upside in Viridian Therapeutics, Inc. (VRDN): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for Viridian Therapeutics, Inc. (VRDN) points to an 89.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of 1.15% and 131.59%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Rani Therapeutics Holdings, Inc. (RANI) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Rani Therapeutics Holdings, Inc. (RANI) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Legend Biotech Corporation Sponsored ADR (LEGN) Stock Jumps 14.2%: Will It Continue to Soar?
by Zacks Equity Research
Legend Biotech Corporation Sponsored ADR (LEGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of -23.26% and 63.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Trevena (TRVN) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Trevena (TRVN) delivered earnings and revenue surprises of 18.18% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Cytek Biosciences, Inc. (CTKB) Q2 Earnings Surpass Estimates
by Zacks Equity Research
Cytek Biosciences, Inc. (CTKB) delivered earnings and revenue surprises of 50% and 2.85%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Berkeley Lights, Inc. (BLI) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Berkeley Lights, Inc. (BLI) delivered earnings and revenue surprises of -26.67% and 14.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Puma Biotech (PBYI) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Puma Biotech (PBYI) delivered earnings and revenue surprises of 950% and 11.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of -6.52% and 66.77%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
VBI Vaccines, Inc. (VBIV) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of 0% and 3.08%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
NGM Biopharmaceuticals (NGM) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 0% and 6.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?